Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE)

Tomoya Mita1,*, Naoto Katakami2,3, Toshihiko Shiraiwa4, Hidenori Yoshii5, Tomio Onuma5, Nobuichi Kuribayashi6, Takeshi Osonoi7, Hideaki Kaneto2, Keisuke Kosugi8, Yutaka Umayahara9, Tsunehiko Yamamoto10, Kazunari Matsumoto11, Hiroki Yokoyama12, Mamiko Tsugawa13, Masahiko Gosho14, Ichiro Shimomura2 and Hirotaka Watada1

Abstract

Background: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is currently used to achieve glycemic targets in patients with type 2 diabetes mellitus (T2DM). The addition of DPP-4 inhibitors to ongoing insulin therapy is expected to reduce insulin dosage, leading to a reduction in the frequency of hypoglycaemia and/or weight gain. Recent studies have demonstrated potential anti-atherosclerotic effects for DPP-4 inhibitors. The aim of the present ongoing study is to assess the effects of sitagliptin on the progression of atherosclerosis in patients with insulin-treated T2DM using carotid intima-media thickness (IMT), an established marker of cardiovascular disease.

Methods and Design: The Sitagliptin Preventive study of Intima media thickness Evaluation (SPIKE) is a prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study. Between February 2012 and September 2012, 282 participants who failed to achieve glycemic control despite insulin therapy were recruited at 12 clinics and randomly allocated to the sitagliptin group (n = 142) or the control group (n = 140). Primary outcomes are changes in maximum and mean IMT of the common carotid artery after 24-month treatment period measured by carotid arterial echography. Secondary outcomes include changes in glycemic control, parameters related to beta-cell function and diabetic nephropathy, occurrence of cardiovascular events and adverse events such as hypoglycaemia, and biochemical markers of vascular function.

Discussion: The present study is designed to assess the effects of sitagliptin on the progression of carotid IMT. Results will be available in the near future, and the findings are expected to provide new strategy to prevent atherosclerosis in patients with insulin-treated T2DM.

Clinical Trial Registration: UMIN000007396

Keywords: Sitagliptin, DPP-4, Diabetes, Atherosclerosis, Intima-media thickness (IMT)
Background

Patients with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular disease (CVD), which are also the most frequent cause of death in these patients [1,2]. Thus, one of the main goals of T2DM management is to reduce the incidence of CVD. T2DM is a metabolic disorder characterized by a decline in insulin secretion and insulin resistance. To reduce blood glucose level, traditional oral hypoglycemic agents (OHA) have been widely used as complementary therapy. Although mono- and combination therapies temporarily improve glycemic control, it is often difficult to maintain long-term glycemic control. Eventually, many patients require insulin therapy in addition to OHA in order to achieve appropriate glycemic control.

Hypoglycaemia and weight gain are common side effects of treatment for T2DM [3] and the major barrier to achieving optimal glycemic control, especially with insulin therapy. Indeed, strict glycemic control using intensive insulin therapy increases the risk of hypoglycaemia threefold [4]. Also, weight gain by insulin therapy was widely observed in clinical studies [5-7]. Recent studies have been given questionable benefits of strict glycemic control, especially using insulin, on CVD in patients with established atherosclerosis or longstanding T2DM [8-10], because frequent episodes of severe hypoglycaemia might reduce their beneficial effects [11] and weight gain may also adversely affect the prognosis. Therefore, several strategies should be employed in order to diminish these adverse effects of insulin therapy. One of the strategies is a reduction in insulin dose by stimulation of endogenous insulin secretion and increased insulin sensitivity using OHA. In fact, treatment with insulin plus metformin [12] and alpha glucosidase inhibitors [13], but not pioglitazone [5] or sulfonylurea [14], were advantageous in avoiding both weight gain and hypoglycaemia. However, there are treatment-limiting side effects for each specific drug. Alpha glucosidase inhibitors are associated with gastrointestinal symptoms including abdominal distension and flatulence [13]. The use of metformin is contraindicated in patients with renal or liver insufficiency and limited in the case of its gastrointestinal side effect [15]. Furthermore, the effects of treatment with insulin plus other traditional OHA on CVD prognosis remain largely unknown. Therefore, new OHA with the least risk of undeliverable effects and multiple beneficial effects on cardiovascular profiles when used with insulin are essential for the treatment of T2DM.

Sitagliptin, the first of a new class of dipeptidyl peptidase-4 (DPP-4) inhibitors, inhibits the degradation of active incretins by DPP-4. Sitagliptin high-selectively and reversibly inhibits DPP-4 compared to other members of the DPP family [16]. Sitagliptin produces approximately 2–3 fold increases in active glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels [16], which stimulates glucose-dependent insulin response [17-19]. GLP-1 decreases hepatic glucose output, glucagon release, gastric emptying, and appetite [20]. Also, GLP-1 seems to have a beneficial effect on functional pancreatic β cell mass [20]. Based on these properties, GLP-1 agonists can significantly decrease body weight, and DPP-4 inhibitors are considered weight neutral, both of which are advantageous relative to the weight gain seen with other OHA [20,21]. Indeed, the addition of sitagliptin to insulin therapy provided significant improvement in glycaemic control without increased risk of hypoglycaemia and clinically-relevant weight gain [22,23]. In addition, these novel agents have potential anti-atherosclerotic properties. GLP-1 directly acts on endothelial cells, vascular smooth muscle cells, monocytes, macrophages, and lymphocytes, and GLP-1 and GLP-1 receptor agonists have been shown to inhibit atherosclerosis and inflammation in rodents [24-26]. Likewise, DPP-4 inhibitors including sitagliptin also reportedly inhibit atherosclerosis and inflammation in both GLP-1-dependent and -independent manners [27,28]. Thus, the addition of DPP-4 inhibitors to insulin therapy is expected to have beneficial effects on CVD in patients with T2DM.

Two recent randomized clinical studies showed that DPP-4 inhibitors did not reduce the risk of CVD, but they also did not increase the risk compared to placebo in T2DM patients with a history of CVD or at risk for CVD [29,30]. These data may suggest that the potential effects of DPP-4 inhibitors in reducing CVD events rates was difficult to demonstrate especially after a relatively short period of treatment and because these subjects have already received a multitude of therapies for other pathologies, including statins, angiotensin inhibitors and antiplatelet agents. On the other hand, good glycemic control at an early stage of T2DM in patients free of history of CVD may increase the chance of significant reduction of not only microvascular disease but also CVD [31]. While early and effective intervention before the development of advanced atherosclerosis may be required to reduce the onset of CVD in CVD-free T2DM patients, it is no doubt difficult in clinical practice to assess the long-term effect of a single drug on primary CVD.

The carotid artery intima-media thickness (IMT) and its progression are considered a surrogate marker for CVD [32-34]. The marker has been widely used as a surrogate endpoint in the evaluation of the effects of intervention on the progression of atherosclerosis. To our knowledge, there are no published studies that have investigated the long-term anti-atherosclerotic effects of sitagliptin in insulin-treated T2DM patients. The present study is a multicenter, randomized, controlled trial designed to compare the effect of adding sitagliptin to insulin treatment on the progression of IMT in CVD-free T2DM patients (sitagliptin group), and sitagliptin-untreated T2DM patients (control group).
Methods and Design

Study design
The Sitagliptin Prospective study of Intima media thickness Evaluation (SPIKE) trial is a prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study. This study has been registered on the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR), which is a non-profit organization in Japan and meets the requirements of the International Committee of Medical Journal Editors (ICMJE) (UMIN000007396).

Study population
Japanese patients with T2DM who regularly attend the Outpatient Diabetes Clinics at 12 institutions in Japan are asked to participate in this study. The inclusion criteria are as follows: 1) T2DM patients in whom the target of blood glucose control specified in the Treatment Guide for Diabetes (Edited by Japan Diabetes Society) [35] was not achieved despite insulin therapy in addition to dietary/exercise therapy or concomitant therapeutic drugs for T2DM other than DPP-4 inhibitors over a period of 3 months or longer. Patients who withdrew from previous treatment with DPP-4 inhibitor for more than 12 weeks are included in the study, 2) ≥30 years of age or older and <80 years of age (regardless of gender), and 3) signing consent form for participation in the study. The following exclusion criteria are also applied: 1) type 1 or secondary diabetes, 2) presence of severe infectious disease, before or after surgery, or severe trauma, 3) history of myocardial infarction, angina pectoris, cerebral stroke, or cerebral infarction, 4) retinopathy requiring laser photocoagulation and/or vitrectomy, or history of these treatments within 1 year, 5) moderate or severe renal dysfunction (serum creatinine in mg/dL: males, >1.4; females, >1.2), 6) severe liver dysfunction (aspartate aminotransferase ≥100 IU/L), 7) moderate or severe heart failure (NYHA/New York Heart Association stage III or severer), 8) treatment with an incretin preparation, such as other DPP-4 inhibitors, at the start of the study, 9) treatment with drugs not concomitantly administrable with incretin preparations with regard to the national health insurance, such as DPP-4 inhibitors, at the start of the study, 10) pregnant, lactating, or possibly pregnant women, or those planning to become pregnant during the study period, 11) past medical history of hypersensitivity to investigational drugs, and 12) patients judged as ineligible by the clinical investigators.

The subjects are screened consecutively, and patients that meet the above eligibility criteria are asked to participate in the present study. All patients who agree to participate are entered into the study. The protocol was approved by the Institutional Review Board of each participating institution in compliance with the Declaration of Helsinki and current legal regulations in Japan. Written informed consent is obtained from all the participants after a full explanation of the study.

Randomization and study intervention
Patients are registered at the administration office of the SPIKE trial via the internet, and once enrolled, they are randomly assigned to either the sitagliptin group or the control group on conventional treatment consisting of drugs other than the DPP-4 inhibitors. Randomization is performed using a dynamic allocation method based on the number of times of insulin injection, with/without pioglitazone, age, and gender.

Patients of the sitagliptin group are started on sitagliptin 25 mg once daily. The dose of sulfonylurea is tapered when considered clinically appropriate in order to avoid hypoglycaemia at the start of sitagliptin. Initiation of treatment with sitagliptin at 50 mg once daily is permitted in patients who are not treated with sulfonylurea. In patients treated with sitagliptin at 25 or 50 mg once daily for 12 weeks, the dose of sitagliptin is increased to a maximum dose of 100 mg once daily when HbA1c is ≥7.0% [35]. The participating physicians are allowed to reduce sitagliptin to 25 or 50 mg/day if treatment with 50 or 100 mg/day is not considered well tolerated. Insulin dose adjustment is also permitted, with priority given to achieve fasting blood glucose of <130 mg/dl and/or 2 hour postprandial blood glucose of <180 mg/dl, as recommended in the Treatment Guide for Diabetes [35]. In the control group, either increasing the dose of current therapy (e.g., insulin) or the addition of sulfonylurea, glinide and alpha glucosidase inhibitors is allowed with the goal of achieving the target value specified in the Treatment Guide for Diabetes (usually HbA1c level <6.9% and/or fasting blood glucose <130 mg/dl and/or 2 hour postprandial blood glucose <180 mg/dl) [35]. The addition of other DPP-4 inhibitors and GLP-1 analogues is banned in the control group. The dose adjustment and addition of metformin and pioglitazone are banned in both groups during study.

In case of hypoglycaemia, the dose of insulin and/or OHA is titrated. Anti-hyperlipidemic and anti-hypertensive drugs are allowed to be used during the study (Figure 1).

Observation variables and schedule
The observation parameters and schedule are shown in Table 1 and Figure 1. The study period is 2 years after registration of the patients (registration period: February 2012 to December 2013; full study duration: February 2012 to June 2016). All randomized participants will be followed until the end of the scheduled study, regardless of adherence to or discontinuation of study medication for any reason. Clinical outcome, adherence, and adverse events will be ascertainment and clinical and biochemical data will be collected at 0, 26, 52, 78, and 104 weeks after randomization.
Study outcome
The primary study outcomes are changes in maximum IMT of the right and left common carotid arteries (max-IMT-CCA) and mean IMT of the right and left CCA (mean-IMT-CCA) during the 24-month (=104 weeks) treatment period, as measured by carotid arterial echography. Investigations are carried out at the start of the study, after 12 months and after 24 months. The secondary outcomes are changes in 1) parameters related to glycemic control and β-cell function (HbA1c, fasting plasma glucose, C-peptide immunoreactivity, and glucagon), 2) parameters related to diabetic nephropathy, including urinary albumin excretion and estimated glomerular filtration rate, 3) lipid profile (total cholesterol, HDL-cholesterol, triglyceride, LDL-cholesterol, and remnant-like particle lipoprotein), 4) occurrence of cardiovascular events, including sudden death, coronary heart disease, and stroke, 5) hypoglycemia and/or any other adverse events, and 6) changes in biochemical variables, including serum intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), 8-hydroxydeoxyguanosine (8-OHDG), thiobarbituric acid reactive substances (TBARS) and adiponectin, 7) changes in treatment-related mental status, and 8) subsets of consenting patients in selected sites are enrolled in substudies designed to assess the effects

Table 1 Items and schedule

| Patient characteristics | Treatment period (weeks) |
|------------------------|--------------------------|
| Patient characteristics | visit 1 (-4 to 0 wks) | visit 2 (0) | visit 3 (26) | visit 4 (52) | visit 5 (78) | visit 6 (104) | At discontinuation |
| Body weight | ○ | ○ | ○ | ○ | ○ | ○ |
| Blood pressure | ○ | ○ | ○ | ○ | ○ |
| Blood chemistry 1* | ○ | ○ | ○ | ○ | ○ | ○ |
| Blood chemistry 2† | ○ | ○ | ○ | ○ | ○ | ○ |
| Urinary albumin excretion | ○ | ○ | ○ | ○ | ○ |
| Carotid IMT | ○ | ○ | ○ | ○ | ○ |
| baPWV and ABI² | ○ | ○ | ○ | ○ | ○ |
| Adherence | ○ | ○ | ○ | ○ | ○ |
| Adverse events | ○ | ○ | ○ | ○ | ○ |

*Including aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase, creatinine, uric acid, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, fasting plasma glucose, HbA1c and amylase.
†Including C-peptide immunoreactivity, glucagon, serum intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), remnant-like particle lipoprotein, 8-hydroxydeoxyguanosine (8-OHDG), thiobarbituric acid reactive substances (TBARS) and adiponectin.
²Including brachial-ankle pulse wave velocity (baPWV) and ankle brachial blood pressure index (ABI).
Examinations were scheduled.
of the intervention on brachial-ankle pulse wave velocity and ankle brachial blood pressure index.

**Safety evaluation**
Details and incidence of adverse events are to be checked periodically.

**Measurement of carotid IMT**
Ultrasoundographic scans of the carotid artery are performed by expert sonographers who are specifically trained to perform the prescribed study examination, as reported previously [36]. To avoid inter-sonographer variability, each participant is examined by the same sonographer with the same equipment (high-resolution B-mode ultrasound scanner equipped with a high frequency (>7.5-MHz) linear transducer, with a limit of detection of <0.1 mm) throughout all the visits. The extracranial CCA, the carotid bulb (Bul), and the internal carotid artery (ICA) in the neck are scanned bilaterally in at least three different longitudinal projections (anterior, lateral, and posterior, which approximately corresponded to 60, 90, 150 degrees for the right carotid artery, and 210, 270, and 300 degrees for the left carotid artery marked on the Meijer’s Arc) as well as transverse projections, and the site of greatest thickness, including plaque lesions, is identified along the arterial walls. In this study, localized elevated lesions with maximum thickness of more than 1 mm, with a point of inflection on the surface of the intima-media complex, are defined as “carotid plaques”, based on the guideline of the Japan Society of Ultrasonics in Medicine [37]. IMT represents the distance between two parallel echogenic lines corresponding to the vascular lumen and the adventitial layer. To avoid inter-reader variability, all scans are electronically stored and emailed to the central office (IMT Evaluation Committee, Osaka, Japan) to be read by a single experienced reader blinded to the clinical characteristics of the patients, in a random order, using automated digital edge-detection software (Intimascope; MediaCross, Tokyo, Japan) [38]. The software system averages 60 points of IMT values in the segment 2 cm proximal to the dilution of the carotid bulb (mean-IMT-CCA). In addition, the greatest thicknesses of IMT, including plaque lesions in the CCA (max-IMT-CCA), the Bul (max-IMT-Bul), and the ICA (max-IMT-ICA), are also measured separately.

**Sample size**
Yokoyama et al. [39] reported previously that the mean (±SD) rate of increase in carotid IMT in diabetic Japanese patients was 0.034 ± 0.054 mm/year and that 1% improvement in HbA1c was associated with 0.02 mm/year improvement in IMT. Based on these results, it is assumed that in a 2-year observation period, registration of at least 232 patients is required to obtain 80% power to detect a difference of 0.04 mm in IMT between the two treatment groups, assuming a standard deviation of 0.108, 15% dropout, and a 0.05 level of significance. Based on this calculation, the target number of enrolled patients is set at 274 for the 2-year registration period.

**Analysis population**
With the exception of patients in whom IMT values are not measured at all during the observation period, data of all participants will be analyzed, regardless of their adherence to the study protocol, using an intent-to-treat approach (ITT).

**Safety and adverse events**
For the sake of patient safety, all adverse events (AEs) would be recorded during the treatment and the follow-ups. AEs are defined as any untoward medical occurrence that results in a subject’s withdrawal from the study or in a clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

The association between an AEs and the study medication must be classed as related or not related to the study drug by an investigator. All related AEs that results in a subject’s withdrawal from the study should be monitored until resolution. Serious AEs are defined as death or life-threatening events, which may require inpatient hospitalization, cause prolongation of existing hospitalization, or even result in persistent or significant disability/incapacity and need intervention to prevent permanent impairment or damage. If participants suffer any AEs/serious AEs, all details will be documented and reported. Furthermore, serious AEs will be reported to the principal investigator, the Data Safety Monitoring Board members (including two cardiologists and a neurologist) and the ethics committee. They can judge whether the diagnosis is appropriate or make a decision on whether the patient should withdraw from the trial based on reports.

**Statistical analysis**
Efficacy will be analyzed using mainly the full analysis set based on the ITT principle and secondarily using the protocol set. To compare the change in IMT at Year 2 (Visit 6, representing the primary endpoint) relative to the baseline, statistical analysis is performed using unpaired t-test and analysis of covariance models that include treatment group, age, gender, baseline IMT, systolic blood pressure, and administration of statins. For the occurrence of cardiovascular events (representing a secondary endpoint), the time to the onset is analyzed and the event rate for each group is estimated using the Kaplan-Meier method and compared using the log-rank test. In addition, Cox proportional hazard model will be applied. The number and percentage of patients who develop adverse events is determined for each group and compared between
the two groups using the Chi-square test. The level of significance is set at 0.05.

Compliance with the Ethical Principles in Clinical Studies and Declaration of Helsinki
The study is to be conducted in accordance with the Ethical Principles in Clinical Studies published by the Ministry of Health, Labour and Welfare of Japan and the ethical principles originating in the Declaration of Helsinki.

Trial organization
The SPIKE study was designed by the principle investigators (Hirotaka Watada, Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan, and Ichiro Shimomura, Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan) through the SPIKE Project Office based at Soiken Inc., Chiyoda-ku, Tokyo, Japan. The principle investigators are responsible for all aspects of trial management, including collecting and cleaning all data, handling of all protocol-related issues, monitoring and optimizing adherence to interventions, adjudicating outcomes, auditing the progress of the study, and determining, executing, and publishing the final study analysis.

Results
Between February 2012 and September 2012, 282 participants were recruited at 12 clinical sites and randomly allocated to either the sitagliptin group (n = 142) or the control group (n = 140). Eight patients were excluded from analyses due to withdrawal from participation. The baseline characteristics of the remaining 274 study participants are listed in Table 2. Of those randomized, 60.2% (n = 165) were male patients and the mean age was 63.7 years. The prevalence of hypertension was 58.8% and that of dyslipidemia was 63.5%. The mean fasting blood glucose level was 154 mg/dL and the mean HbA1c was 8.0%.

Discussion
The aim of this study is to investigate the effects of sitagliptin on the progression of atherosclerosis in insulin-treated patients with T2DM free of history of CVD, using common carotid IMT, a widely used surrogate marker of atherosclerosis. Patients with type 1 diabetes mellitus [46]. Similarly, multiple interventions that included insulin therapy, reduced the risk of CVD in the Steno study [47]. These data suggest that the use of insulin itself did not have deleterious effect on CVD prognosis. Nevertheless, recent studies questioned the benefits of strict glycaemic control, especially using insulin, on CVD in patients with established atherosclerosis or long-standing diabetes [8-10]. These might be largely affected by frequent episodes of severe hypoglycaemia [11] and weight gain with intensive insulin therapy. To reduce these negative aspects of insulin therapy, combination therapy of insulin plus other OHA might be one therapeutic option. The addition of DPP-4 inhibitors on ongoing insulin therapy was reported to have specific advantages on reduced frequency of hypoglycaemia and weight gain in addition to the expected benefits associated with glycemic control and limiting insulin dose [20,21]. Therefore, we expected that DPP-4 inhibitors added to on ongoing insulin therapy have beneficial effects on risk of CVD.

DPP-4 inhibitors may have unique direct beneficial effects on the progression of atherosclerosis in addition to the expected advantages described above in the case of co-administration with insulin. Experimental studies using animal models have shown anti-atherosclerotic effect for sitagliptin. For instance, Matsubara et al. [27] showed that inhabitation of macrophage inflammation by enhancing GLP-1 signalling with sitagliptin reduced atherosclerotic lesion formation in apoE-deficient mice. In addition, we and others recently demonstrated that other kinds of DPP-4 inhibitors also reduce the plaque burden at the level of the aortic sinuses accompanied by macrophage infiltration in animal model of atherosclerosis [28,48]. Furthermore, studies in rats demonstrated that treatment with sitagliptin reduced neointimal formation at 4 weeks after arterial injury [49]. These data suggest that DPP-4 inhibitors may have unique anti-atherosclerotic effects in patients with T2DM. Indeed, it was demonstrated that sitagliptin reduced monocyte inflammation in patients with T2DM independent of its glucose lowering effect [50]. Another study showed that sitagliptin improved endothelial dysfunction and inflammation in subjects with CVD and uncontrolled T2DM beyond its glucose lowering effect [51]. These effects may be mediated by blockade of degradation of a direct substrate of DPP-4, stromal cell-derived factor-1 (SDF-1), which is a chemokine known to stimulate bone marrow mobilization of endothelial progenitor cells (EPCs). In this regard, one recent study suggested that sitagliptin increased the number of circulating EPCs in T2DM patients with up-regulation of serum SDF-1, potentially leading to reduced progression of atherosclerosis as assessed by the expression of proinflammatory mediators and endothelial function [40-43]. Some observational studies reported a relationship between hyperinsulinemia and increased risk of CVD [44,45]. However, the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complication (DCCT/EDIC) study indicated that intensive treatment with insulin had long-term positive effects on CVD in patients with type 1 diabetes mellitus [46].
of atherosclerosis [52]. Taken together, the results of the above preclinical and clinical studies have yielded new mechanistic insight and provided support to the beneficial effects of sitagliptin on CVD risk.

In contrast, two recent randomized short-term clinical studies showed that DPP-4 inhibitors neither reduced nor increased the risk of CVD compared to placebo in T2DM patients with history of CVD or at high risk for CVD [29,30]. With regard to sitagliptin, the randomized, placebo-controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study has already commenced evaluation of the effects of sitagliptin on CVD in 14,000 patients with T2DM with longer duration of study period than other studies [53]. This study may provide further insight into the effects of DPP-4 inhibitors on prevention of CVD.

Recently, it was reported that short-term treatment with both sitagliptin and vildagliptin reduced the progression of IMT in subanalysis of a small number patients without a control group [54]. However, the results are probably limited by the design and sample size. On the other hand, the present study is designed to clarify the efficacy and benefits of sitagliptin in preventing the progression of atherosclerosis in patients with insulin-treated T2DM free of apparent CVD in a multicenter PROBE trial. We used surrogate endpoints in this trial due to practical constraints, including trial costs and concern about feasibility in relation to long-term intervention. Carotid ultrasonographic measurements of IMT have been validated against pathologic specimens, and were demonstrated to be strong predictors of CVD in subjects with and without T2DM [27,28]. It has also been shown that changes in carotid IMT over time correlate with the rate of future CVD [34].

The results will become available in the near future, and the findings might hold great clinical relevance to the prevention of atherosclerosis and subsequent CVD in patients with insulin-treated T2DM. The results from this clinical trial will be submitted for publication in 2014.

### Table 2: Clinical characteristics of randomized participants in SPIKE

| Parameters                                    | Mean ± SD       |
|-----------------------------------------------|-----------------|
| Gender (females/males) (%)                    | 109 / 165 (39.8 / 60.2) |
| Age (years)                                   | 63.7 ± 9.8      |
| Current smoking                               | 59 (21.5)       |
| Current alcohol                               | 121 (44.2)      |
| Hypertension                                  | 161 (58.8)      |
| Dyslipidemia                                  | 174 (63.5)      |
| Duration of diabetes (years)                  | 17.3 ± 6.6      |
| Hba1c (%)                                     | 8.0 ± 1.0       |
| Fasting plasma glucose (mg/dl)                | 154.0 ± 48.9    |
| C-peptide immunoreactivity (ng/ml)            | 1.2 ± 0.8       |
| Glucagon (pg/ml)                              | 805.0 ± 25.1    |
| Body mass index (kg/m²)                       | 250.0 ± 40.0    |
| Systolic blood pressure (mmHg)                | 131.1 ± 15.0    |
| Diastolic blood pressure (mmHg)               | 74.9 ± 11.5     |
| Total-cholesterol (mg/dl)                     | 192.5 ± 34.3    |
| HDL-cholesterol (mg/dl)                       | 55.1 ± 14.5     |
| Triglyceride (mg/dl)                          | 129.3 ± 100.7   |
| LDL-cholesterol (mg/dl)                       | 108.9 ± 28.7    |
| Remnant-like particle lipoprotein (mg/dl)     | 5.1 ± 6.3       |
| Serum creatinine (mg/dl)                      | 0.7 ± 0.2       |
| urinary albumin excretion (mg/g Cr)           | 19.3 [8.3-83.7] |
| Serum uric acid (mg/dl)                       | 5.3 ± 1.3       |
| Amylase (U/l)                                 | 700.0 ± 345.0   |
| Serum ICAM-1 (ng/ml)                          | 255.8 ± 90.9    |
| Serum VCAM-1 (ng/ml)                          | 833.6 ± 340.3   |
| IL-6 (pg/ml)                                  | 1.8 [1.2-2.9]   |
| hsCRP (mg/dl)                                 | 0.050 [0.024-0.116] |

#### (Continued)

| Parameters                                    | Number (%) |
|-----------------------------------------------|------------|
| Oral glucose-lowering agents                  | 169 (61.7) |
| Metformin                                     | 97 (35.4)  |
| Sulfonylurea                                   | 32 (11.7)  |
| Glinides                                       | 21 (7.7)   |
| Thiazolidinediones                             | 24 (8.8)   |
| α-glucosidase inhibitor                        | 83 (30.3)  |
| Anti-hypertensive drugs                        | 147 (53.6) |
| ACE inhibitors                                 | 12 (4.4)   |
| ARBs                                          | 122 (44.5) |
| Thiazides                                      | 25 (9.1)   |
| CCB                                           | 84 (30.7)  |
| Others                                        | 18 (6.6)   |
| Lipid-lowering agents                          | 145 (52.9) |

Data are number (%) or mean ± SD, or *median [range].

ICAM-1, Intercellular adhesion molecule 1; VCAM-1, Vascular cell adhesion molecule 1; IL-6, Interleukin 6; hs-CRP, High-sensitivity C-reactive protein; ACE, Angiotensin-converting enzyme; ARB, Angiotensin II receptor blocker; CCB, Calcium channel blocker.
Abbreviations
Bul Blb; CCA: Common carotid artery; CVD: Cardiovascular disease; DCCT/EDIC: Diabetes control and complications trial/epidemiology of diabetes intervention and complication; EPS: Endothelial progenitor cells; GLP-1: Glucagon-like peptide-1; GIP: Glucose-dependent insulinotropic polypeptide; hCRP: High-sensitivity C-reactive protein; ICA: Internal carotid artery; ICMI: International Committee of Medical Journal Editors; ICAM-1: Intercellular adhesion molecule 1; IL-6: Interleukin 6; IMT: Intima-media thickness; ITT: Intent-to-treat approach; TGDM: Type 2 diabetes mellitus; OHA: Oral hypoglycemic agents; B-OH-DG: 8-hydroxy-2'-deoxyguanosine; PROBE: Prospective, randomized, open label, blinded-endpoint; SDF-1: Stromal cell-derived factor-1; SPIKE: Sitagliptin Prospective study of Intima media thickness Evaluation; TBA5: Thebarbital acid reactive substances; TECOS: Trial Evaluating Cardiovascular Outcomes with Sitagliptin; UMIN-CTR: University Hospital Medical Information Network Clinical Trials Registry; VCAM-1: Vascular cell adhesion molecule 1.

Competing interest
TM received research funds from MSD, Takeda and Eli Lilly. NKA is a staff member of the endowed chair (the Department of Metabolism and Atherosclerosis) donated from Kowa Pharmaceutical Co. Ltd., and has received lecture fees from Astellas Pharma Inc., AsstenaZeka KK, Daiichi Sankyo Inc., Dakinoppon Sumitomo Pharma Co., Eli Lilly, Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., MSD, Novartis Pharmaceuticals, Nordisk Pharma, Ono Pharmaceutical Co., Otsuka Pharmaceutical, Shionogi & Co., Ltd., Takeda Pharmaceutical Co., Teijin Pharma, Sanofi-Aventis. NKA has received lecture fees from Sanofi-Aventis, Eli Lilly. TO has received lecture fees from Boehringer Ingelheim, Sanofi-Aventis, Ono Pharmaceutical Co., Novo Nordisk Pharma, Kissei Pharma, Mitsubishi Tanabe Pharma, Novartis Pharmaceuticals, Sanwalkagaku Kenkyusho, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., MSD, Dakinoppon Sumitomo Pharma, Kowa Co. and research funds from Novo Nordisk Pharma, Dakinoppon Sumitomo Pharma. HK has received lecture fees from Boehringer Ingelheim, Sanofi-Aventis, Ono Pharmaceutical Co., MSD, Novo Nordisk Pharma, Novartis Pharmaceuticals, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., Dakinoppon Sumitomo Pharma Co., Mitsuibishi Tanabe Pharma Co., Kyowa Kirin, and research fees from Takeda Pharmaceutical Co., MSD, Mochida Pharmaceutical Co. Sanofi-Aventis, Novartis Pharmaceuticals, Novo Nordisk Pharma, Eli Lilly, Daiichi Sankyo Inc., Shionogi Pharma, Teijin Pharma, Dakinoppon Sumitomo Pharma Co., Otsuka Pharmaceutical, Kissei Pharmaceutical Co. KK has received lecture fees from Boehringer Ingelheim, Sanofi-Aventis, Novo Nordisk Pharma, Novartis Pharmaceuticals, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., MSD, Dakinoppon Sumitomo Pharma, Kowa Co. and research fees from Sanofi-Aventis, Novo Nordisk Pharma, Novartis Pharmaceuticals, Sanwalkagaku Kenkyusho, Takeda Pharmaceutical Co., MSD, MT has received lecture fees from Novo Nordisk Pharmaceuticals, Sanofi-Aventis, Kowa Hakko Kirin Co., Novo Nordisk Pharma, Kowa Co. MG has received lecture fees from Novartis. IS has received lecture fees from Astellas Pharma Inc., AsstenaZeka KK, MSD KK, Ono Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd, Kissei Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd, Sanwa Kagaku Kenkyusho Co., Ltd, Daiichi Sankyo Co., Ltd, Takeda Pharma KK, Mitsubishi Tanabe Pharma Co., Teijin Pharma Ltd, Eli Lilly Japan KK, Niippon Boehringer Ingelheim Co., Ltd, Novartis Pharma KK, Novo Nordisk Pharma Ltd, Bayer Yakuhin Ltd, Pfizer Japan Inc, Bristol-Myers KK, Mochida Pharmaceutical Co., Ltd. and research funds from Astellas Pharma Inc., AsstenaZeka KK, Eisai Co., Ltd., MSD KK, Otsuka Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Kaken Pharmaceutical Co., Ltd, Kissei Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd, Sanofi KK, Shionogi & Co., Ltd, Daiichi Sankyo Co., Ltd, Dakinoppon Sumitomo Pharma Co., Ltd, Takeda Pharma KK, Mitsubishi Tanabe Pharma Co., Teijin Pharma Ltd, Niippon Boehringer Ingelheim Co., Ltd, Novartis Pharma KK, Novo Nordisk Pharma Ltd, Pfizer Japan Inc, Bristol-Myers KK, Mochida Pharmaceutical Co., Ltd, Eli Lilly Japan KK. HW has received lecture fees from Boehringer Ingelheim, Sanofi-Aventis, Ono Pharmaceutical Co., Novo Nordisk Pharma, Novartis Pharmaceuticals, Eli Lilly, Sanwalkagaku Kenkyusho, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., MSD, Dakinoppon Sumitomo Pharm., Kowa Co. and research funds from Boehringer Ingelheim, Pfizer, Mochida Pharmaceutical Co., Sanofi-Aventis, Novo Nordisk Pharma, Novartis Pharmaceuticals, Sanwalkagaku Kenkyusho.

Authors’ contributions
The authors meet the criteria for authorship recommended by the International Committee of Medical Journal Editors (ICMJE) and take full responsibility for all contents of the manuscript and editorial decisions. All authors contribute to the study design and were involved at all stages of manuscript development. TM and NG drafted the manuscript based on the protocol. MG contributes to analysis of research data. All authors were involved in analysis and interpretation of data, reviewed/editied the manuscript and approved the final manuscript. IS and HW were the principal guarantors of this work and have full access to all the data in the study and take responsibility for the integrity of the data and accuracy of data analysis.

Authors’ information
Collaborators on Sitagliptin Preventive study of Intima media thickness Evaluation (SPIKE) Trial; (listed in alphabetical order)

Financial support for this study was provided by the Japan Society for Patient Reported Outcome, which is a general incorporated association. The Japan Society for Patient Reported Outcome received research funds from Mitsubishi Tanabe, Ono and Novo Nordisk.

Author details
1Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Hongo 2-11, Bunkyo-ku, Tokyo 113-8421, Japan.
2Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan.
3Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan.
4Shiraiwa medical clinic: Teshihiko Shiraiwa

Acknowledgement
We thank all the patients who participated in this study and all the staff at 12 participating institutions.

Founding sources: (listed in alphabetical order)

Author details
1Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Hongo 2-11, Bunkyo-ku, Tokyo 113-8421, Japan.
2Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan.
3Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan.
4Shiraiwa medical clinic: Teshihiko Shiraiwa

Acknowledgement
We thank all the patients who participated in this study and all the staff at 12 participating institutions.

Founding sources: (listed in alphabetical order)

Financial support for this study was provided by the Japan Society for Patient Reported Outcome, which is a general incorporated association. The Japan Society for Patient Reported Outcome received research funds from Mitsubishi Tanabe, Ono and Novo Nordisk.

Author details
1Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Hongo 2-11, Bunkyo-ku, Tokyo 113-8421, Japan.
2Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan.
3Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan.
4Shiraiwa medical clinic: Teshihiko Shiraiwa

Acknowledgement
We thank all the patients who participated in this study and all the staff at 12 participating institutions.

Founding sources: (listed in alphabetical order)

Financial support for this study was provided by the Japan Society for Patient Reported Outcome, which is a general incorporated association. The Japan Society for Patient Reported Outcome received research funds from Mitsubishi Tanabe, Ono and Novo Nordisk.

Author details
1Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Hongo 2-11, Bunkyo-ku, Tokyo 113-8421, Japan.
2Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan.
3Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan.
4Shiraiwa medical clinic: Teshihiko Shiraiwa

Acknowledgement
We thank all the patients who participated in this study and all the staff at 12 participating institutions.

Founding sources: (listed in alphabetical order)

Financial support for this study was provided by the Japan Society for Patient Reported Outcome, which is a general incorporated association. The Japan Society for Patient Reported Outcome received research funds from Mitsubishi Tanabe, Ono and Novo Nordisk.
References

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1999, 340:139–144.

2. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16(2):434–444.

3. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC,geddfal WS: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2560–2572.

4. Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohsaka K, Koshiba M, Horiuchi Y, Ikizaka Y, Kinoshita M, Nakamura T: Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001, 50(5):583–589.

5. Lovshin JA, Drucker DJ: Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5(5):262–269.

6. Aoki K, Mitani T, Azuma K, Ikeda H, Iida K, Miyagawa J, Namba M: Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Endocr J 2013, 60(3):733–742.

7. Shimoda S, Iwasaki S, Ishimori S, Mano T, Goto H, Maeda T, Matsuoi T, Sekigami T, Kawashima J, Kondo T, Masumura T, Motoshima H, Furukawa N, Nishida K, Araki E: Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. Endocr J 2013, 60:1207–1214.

8. Arakawa M, Mitani T, Azuma K, Kato R, Goto H, Nomiya J, Fujitani Y, Hirose T, Kaminato R, Watada H: Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59(4):1030–1037.

9. Goto H, Nomiya T, Mitani T, Yasunari E, Azuma K, Komiya K, Arakawa M, Jin WL, Kanazawa A, Kaminato R, Fujitani Y, Hirose T, Watada H: Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after coronary injury. Biochem Biophys Res Commun 2011, 405:79–84.

10. Mitani T, Watada H: Glucagon-like Peptide-1 and atherosclerosis. Cardiovasc Hematol Agents Med Chem 2012, 10(4):309–318.

11. Matsuoka J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohsaka K, Koshiba M, Horiuchi Y, Ikizaka Y, Kinoshita M, Nakamura T, Atlas H, Nomiya J, Watada H: A DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apoE-deficient mice. Endocrinology 2013, 154:1260–1270.

12. White WB, Cannon CP, Heller SR, Nissen SE, Bergeman RM, Bakris GL, Perez AT, Fleck MR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, Investigators E: Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013, 369:1327–1335.

13. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Ubeda JA, Desei NR, Morganzon O, McGuire DK, Ray KK, Leiter LA, Raz I, Committee S-TS: Investigators: Saxaglitipin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369:1317–1326.

14. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577–1589.

15. Yamazaki Y, Kodama M, Nishizawa H, Sakamoto K, Matsuishi M, Kajimoto Y, Kosugi K, Shimizu Y, Kaminato R, Hori M: Carotid intima-media thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease. Diabetes Care 2000, 23(9):1310–1315.

16. Yoshida M, Mitani T, Yamamoto R, Shimizu T, Ikeda F, Ohmura C, Kanazawa A, Hirose T, Kaminato R, Watada H: Combination of the Framingham risk score and carotid intima-media thickness improves the prediction of cardiovascular events in patients with type 2 diabetes. Diabetes Care 2012, 35(1):178–180.

17. Okayama KI, Mitani T, Goto H, Yamamoto R, Yoshida M, Kanazawa A, Kaminato R, Fujitani Y, Watada H: Carotid-intima-media thickness progression predicts cardiovascular events in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2013, 101(3):286–292.

18. Society TID: Treatment Guide for Diabetes, ed by the Editorial Committee Members o "Treatment Guide for Diabetes" (Araki E, Iwamoto Y, Kadowaki T, Kashiwagi A, Kitada M, Nanjo K, Tajima N). Bunkado Co, Ltd, Tokyo, Japan 2010.

19. Katakami N, Mitani T, Yoshii H, Onuma T, Kaneto H, Osono T, Shiroma T, Shiroma T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kurihata Y, Jinnouchi M, Nomiya J, Watada H, Shimomura I: Rational, design, and baseline.
characters of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-a). J Atheroscler Thromb 2013, 20(12):893–902.

37. Termination and Diagnostic Criteria Committee JSaUM: Subcommittee for preparing guidelines for ultrasound diagnosis of carotid artery: standard method for ultrasound evaluation of carotid artery lesions. Jpn J Med Ultrasonics 2009, 36:501–518.

38. Yanase T, Nasu S, Mukuta Y, Shimizu Y, Nishihara T, Okabe T, Nomura M, Inoguchi T, Nawata H: Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope. Am J Hypertens 2006, 19(12):106–1212.

39. Yokoyama H, Katakami N, Yamasaki Y: Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Stroke 2006, 37(9):2420–2427.

40. Iida KT, Shimano H, Kawakami Y, Sone H, Toyoshima H, Suzuki S, Asano T, Okuda Y, Yamada N: Insulin up-regulates tumor necrosis factor-alpha production in macrophages through an extracellular-regulated kinase-dependent pathway. J Biol Chem 2001, 276(35):32531–32537.

41. Mita T, Goto H, Azuma K, Jin WA, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H: Impact of insulin resistance on enhanced monocyte adhesion to endothelial cells and atherosclerogenesis independent of LDL cholesterol level. Biochem Biophys Res Commun 2010, 395(4):477–483.

42. Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisakumi YY, Bursell S, Yanagisawa M, King GL, Kahn CR: The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest 2003, 111(9):1373–1380.

43. Schneider DJ, Absher PM, Ricci MA: Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells. Circulation 1997, 96(9):2868–2876.

44. Janka HU, Ziegler AG, Standl E, Mehnert H: Daily insulin dose as a predictor of macrovascular disease in insulin treated non-insulin-dependent diabetics. Diabetes Metab 1987, 13:359–364.

45. Liu QZ, Knowler WC, Nelson RG, Saad MF, Charles MA, Liebow IM, Bennett PH, Pettitt DJ: Insulin treatment, endogenous insulin concentration, and ECG abnormalities in diabetic Pima Indians. Cross-sectional and prospective analyses. Diabetes 1992, 41(9):1141–1150.

46. Nathan DM, Cleary PA, Backlund YJ, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Complications Trial/Epidemiology of Diabetes Interventions and Outcomes Study (SPIKE). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643–2653.

47. Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999, 353(9153):617–622.

48. Shah Z, Kampfrath T, Deulius JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, Sun Q, Mihal G, Maiseyue A, Rajagopalan S: Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011, 124:2338–2349.

49. Lim S, Choi SH, Shin H, Cho BJ, Park HS, Ahn BY, Kang SM, Yoon JW, Jang HC, Kim YB, Park KS: Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. PLoS one 2012, 7:e55007.

50. Satoh-Asahara N, Saaki Y, Wada H, Tochuya M, Iguchi A, Nakagawachi R, Odori S, Kono S, Hasegawa K, Shintatsu A: A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism 2013, 62(3):347–351.

51. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujiseke K, Yamamoto E, Kakita K, Hokimoto S, Jinnoouchi H, Ogawa H: Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 2013, 77:1337–1344.

52. Fadini GP, Boscaro E, Albiero M, Menegazz L, Frison V, de Kreutzenberg S, Agostini C, Tiengo A, Avogaro A: The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010, 33(7):1607–1609.

53. Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, Califf RM, Holman RR: Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013, 166(6):983–989. e987.

54. Barbieri M, Rizzo MR, Marfella R, Boccardi V, Esposito A, Pansini A, Paolillo G: Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-4 inhibitor. Atherosclerosis 2013, 227(2):349–354.

Cite this article as: Mita et al.: Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE). Diabetology & Metabolic Syndrome 2014 6:35.